Antithrombotic therapy and bleeding risk in atrial fibrillation. Fewer unanswered questions

Thrombosis and Haemostasis

Volumn 109, Issue 3, 2013, Pages 363-365

  Ruiz Nodar, Juan M ^a   Marín, Francisco ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BARE METAL STENT; BLEEDING; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; HAS BLED SCORE; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; THROMBOSIS;

EID: 84874783908     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-01-0058     Document Type: Letter

References (23)

1. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
2. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137: 263-272.
3. Keogh C, Wallace E, Dillon C, et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and metaanalysis. Throm Haemost 2011; 106: 528-538.
4. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Throm Haemost 2012; 107: 1172-1179.
5. Friberg L RM, Lip GYH. Net clinical benefit of warfarin in patients with atrial fibrillation. Circulation 2012; 125: 2298-2307.
6. Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
7. Rodríguez-Mañero M, Cordero A, Bertomeu-González V, et al. Impacto de los nuevos criterios para el tratamiento anticoagulante de la fibrilación auricular. Rev Esp Cardiol 2011; 64: 649-653.
8. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26: 1471-1477.
9. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 46: 1511-1517.
10. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ACTIVE Investigators, N Engl J Med 2009; 360: 2066-2078.
11. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
12. Pisters R, Lane DA, Nieuwlaat R, et al. A Novel User-Friendly Score (HAS-BLED) to assess oneyear risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
13. Gallego P, Roldán V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events and mortality in patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012; 5: 312-318.
14. Ruiz-Nodar JM, Marín F, Roldán V, et al. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv 2012; 5: 459-466.
15. Azoulay L, Dell'Aniello S, Simon T, et al. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thromb Haemost 2013; 109: 431-439.
16. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
17. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
18. Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Throm Haemost 2011; 106: 569-571.
19. Nabauer M, Gerth A, Limbourg S, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-434.
20. Ruiz-Nodar JM, Marín F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation: implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51: 818-825.
21. Ruiz-Nodar JM, Marín F, Sánchez-Paya J, et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J 2009; 30: 932-939.
22. Ruiz-Nodar JM, Marín F, Lip GYH. Antithrombotic Management and Type of Stent in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Rev Esp Cardiol 2013; 66: 12-16.
23. Connolly SJ, Eikelboom JW, Hirst J, et al; on behalf of the ACTIVE steering committee and investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011; 155: 579-586.